Valneva is withdrawing its Chikungunya vaccine from the US market due to safety concerns. The move comes as the FDA has suspended the license for the vaccine, and an investigation is underway. The situation surrounding the vaccine's withdrawal appears to be part of a broader landscape of vaccine development and regulatory activity, with various other vaccine-related news and developments also being reported.